

LOGICA trial

*“Laparoscopic versus **O**pen Gastrectomy for **G**astric **C**ancer – a multicenter prospectively randomized controlled trial”*

Achtergrond

Nieuwe gevallen maagkanker


Wereld = 1 miljoen (5^e)

Azië = 0,5 miljoen

NL = 1500

Incidence ASR

Both sexes



Stomach cancer

- 11.0+
- 7.4-11.0
- 5.2-7.4
- 3.5-5.2
- <3.5
- No data

International Agency for Research on Cancer



Achtergrond


- Diagnose maagkanker
 - 5-jaarsoverleving 20-25%
- Curatief (33%): Chirurgische resectie
 - 5-jaarsoverleving ~45%
- Perioperatief chemotherapie
 - 5-jaarsoverleving + 10%

Nederlandse Kankerregistratie

Hartgrink, J Clin Oncol 2004

Ronellenfitch , Cochrane 2013.

Achtergrond



- Maagresectie
- Lymfeklierdissectie
- Reconstructie

Nederland (2013)

- 75 % Open
- 25 % Laparoscopisch

Laparoscopie vs. Open

Meta-analyses

- Minder bloedverlies
- Minder complicaties
- Kortere ligduur
- Gelijke oncologische uitkomsten (R0, lymfeklieren, 5-jaars overleving)

Voornamelijk Aziatische studies:

- Hoge prevalentie
- Screening → Andere patientenpopulatie (tumorstadium, leeftijd)



*“Laparoscopic versus **O**pen Gastrectomy for **G**astric **C**ancer – a multicenter prospectively randomized controlled trial”*



Doel

Het vergelijken van laparoscopische vs. open maagresectie

Hypothese

Laparoscopische maagresectie:

- een beter en sneller postoperatief herstel
- vergelijkbare oncologische uitkomsten

In- en exclusie criteria




- Histologisch bewezen adenocarcinoom maag
- Chirurgisch resectabele tumor (cT1-4a,N0-3b,M0)
- Leeftijd ≥ 18
- European Clinical Oncology Group (ECOG) performance status 0,1 of 2
- Informed consent



-
- Siewert type I cardiacarcinoom
 - Zwangerschap


Studie opzet



Totale + Distale maagresectie



Chirurgische procedure

- Distale / totale maagresectie
- Roux-en-Y reconstructie
- Esophagojejunostomie
- Jejunumpouch optioneel



Lymfeklierdissectie – D2

Distal gastrectomy	Total gastrectomy
D1: Station 1,3,4sb, 4d, 5, 6, 7	D1: Station 1-7
D1+: Station 1,3,4sb, 4d, 5, 6, 7, 8, 9	D1+: Station 1-7, 8, 9, 11p
D2: Station 1,3,4sb, 4d, 5, 6, 7, 8, 9, 11p, 12a	D2: Station 1-7, 8, 9, 11p, 11d, 12a



- 1 Right paracardial
- 2 Left paracardial
- 3 Lesser curvature
- 4sa Short gastric
- 4sb Left gastroepiploic
- 4d Right gastroepiploic
- 5 Suprapyloric
- 6 Infrapyloric
- 7 Left gastric artery
- 8a Anterior common hepatic
- 8b Posterior common hepatic
- 9 Celiac artery
- 10 Splenic hilum
- 11p Proximal splenic
- 11d Distal splenic
- 12a Left hepatoduodenal
- 12b.p Post-hepatoduod
- 13 Retropancreatic
- 14v Superior mesenteric v.
- 14a Superior mesenteric a.
- 15 Middle colic
- 16a Aortic hiatus
- 16a2,b Paraaortic, middle
- 16b2 Paraaortic, caudal
- 17 Anterior pancreatic
- 18 Inferior pancreatic
- 19 Infradiaphragmatic
- 20 Esophageal hiatus
- 110 Lower paraesophag.
- 111 Supradiaphragmatic
- 112 Post-mediastinal

Perioperatief protocol

- Preoperatief bijvoeden: MUST score ≥ 2
- Epiduraal: Optioneel bij open
- Maagsonde: nee
- Buikdrain: nee
- Thoraxdrain: nee
- Jejunumfistel: nee
- Voeden: Start op dag 1 postoperatief

Protocol: ERAS

	Summary and recommendations	Evidence level	Recommendation grade
Wound catheters and TAP block	Evidence is conflicting regarding wound catheters in abdominal surgery	Wound catheters: Low to moderate	Weak
	Evidence is strong in support of TAP block in abdominal surgery in general, although the effect is evident only during the first 48 h after surgery and none of the evidence is from gastrectomies	TAP blocks: Low	Weak
Nasogastric/nasojejunal decompression	Nasogastric tubes should not be used routinely in the setting of enhanced recovery protocols in gastric surgery	High	Strong
Perianastomotic drains	Avoiding the use of abdominal drains may reduce drain-related complications and shorten hospital stay after gastrectomy	High	Strong
Early postoperative diet and artificial nutrition	Patients undergoing total gastrectomy should be offered drink and food at will from POD 1. They should be advised to begin cautiously and increase intake according to tolerance	Moderate	Weak
	Patients clearly malnourished or those unable to meet 60% of daily requirements by POD 6 should be given individualized nutritional support	Moderate	Strong
Audit	Systematic audit improves compliance and clinical outcomes	Low	Strong

Primaire uitkomstmaat

- Postoperatieve ligduur

Ontslagcriteria:

- Adequate pijn controle met orale medicatie (VAS-score <5)
- Gestart met mobilisatie
- Adequate voedingsintake en onafhankelijk van intraveneuze vloeistoffen

Secundaire uitkomstmaten

- Kosteneffectiviteit
- Oncologische uitkomsten (lymfeklieren, R0)
- Postoperatieve morbiditeit and mortaliteit
- Heropnames
- Kwaliteit van Leven (EQ-5D-5L, EORTC)
- Overleving

Aditionele metingen

Pre-OK	Post-OK	
2x Bloedafname (1 biobank)	Bloedafname	Direct postoperatief, POD 1 (& 2)
Biopsie (biobank)	VAS-score	POD 1 & 2
KvL vragenlijsten	KvL vragenlijsten	6 wkn & 6, 12, 24, 36, 48, 60 mnd

- KvL : alle centra
- Bloedafname: alle centra
- Biobank: selectief



Sample size

Op afname ligduur 18 → 14 dagen

n = 210

Haalbaarheid

Maagresecties 2013 (DUCA) x 40% inclusie

n = 266


“One day course
on minimally
invasive
gastrectomy”

General Information

Date: **March 14th 2014**
Target Group: This day is set up for surgeons and OR nurses
Certification: Dutch Society for Surgery
Accreditation: 6 points by NVvH
Location: Refereerruimte stafgang Heelkunde (G04.206)
UMC Utrecht
Heidelberglaan 100
3584 CX Utrecht
The Netherlands
Registration: You can register by filling and return attached registration card or e-mail to r.liesdek@umcutrecht.nl
Registration fee: Surgeons: € 175
OR nurses: € 50

The registration fee can be paid to the account number of the Stichting Chirurgische Oncologie Utrecht: ING 5270359 stating Gastric day UMCU.

Information: Department of Surgery, UMC Utrecht
Tel: +31 (0)88-7558074
Fax: +31 (0)30-2541944
E-mail: t.j.weijs@umcutrecht.nl
Supported by: Covidien, Storz, Nycomed



Subsidies



ZonMw

Johnson & Johnson



Hylke Brenkman - h.j.f.brenkman@umcutrecht.nl
Maarten Seesing - m.f.j.seesing@umcutrecht.nl